Cambridge Nutritional Sciences plc (AIM:CNSL)
1.391
-0.059 (-4.07%)
Nov 20, 2026, 8:44 AM GMT
AIM:CNSL Revenue
Cambridge Nutritional Sciences had revenue of 2.36M GBP in the half year ending September 30, 2026, a decrease of -42.94%. This brings the company's total for the last twelve months to 5.47M, down -32.11% year-over-year. In the fiscal year ending March 31, 2026, Cambridge Nutritional Sciences had annual revenue of 6.98M, down -16.27%. That makes Cambridge Nutritional Sciences the 38,756th largest company in the world by revenue and 743rd in the United Kingdom.
Revenue (ttm)
5.47M
Revenue Growth
-32.11%
P/S Ratio
0.60
Revenue / Employee
64.36K
Employees
85
Market Cap
3.31M
Revenue by Geography
- United Kingdom 1.66M 23.8%
- Rest of Europe 1.55M 22.2%
- Asia and The Far East 1.46M 20.9%
- Americas 998.00K 14.3%
- India 845.00K 12.1%
- Africa and The Middle East 468.00K 6.7%
Fiscal year ended Mar 31, 2026 See the full AIM:CNSL breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.98M | -1.36M | -16.27% |
| Mar 31, 2025 | 8.33M | -1.44M | -14.77% |
| Mar 31, 2024 | 9.77M | 2.23M | 29.53% |
| Mar 31, 2023 | 7.55M | -993.00K | -11.63% |
| Mar 31, 2022 | 8.54M | 1.72M | 25.28% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 46.99B |
| GSK plc | 33.54B |
| Haleon | 11.15B |
| Smith & Nephew | 4.77B |
| Proteome Sciences | 3.77M |
| GENinCode | 2.60M |
| Futura Medical | 2.32M |
| OptiBiotix Health | 1.29M |